Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)
Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.005
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2017
Authors
Publisher
Elsevier BV